Hospital Infection Therapeutics Market Will Experience a Noticeable Growth during the Forecast Period 2020 – 2027Last Updated: July 30th, 2020
According to a new market report published by Research Corridor “Hospital Infection Therapeutics Market (Drug Type: Antibacterial, Antiviral, and Antifungal Drugs; Infection Type: Hospital-Acquired Pneumonia, Urinary Tract Infections, Gastrointestinal Disorders, Bloodstream Infections, Surgical Site Infections, and Other Hospital Infections) – Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast 2020 – 2027” the hospital infection therapeutics market was valued over USD 3 billion in 2019 and is expected to grow at a CAGR of over 4% from 2020 to 2027.
Hospital infections, commonly known as hospital-acquired infections (HAIs) or nosocomial infections, are referred to infections that develop in patients undergoing treatment in a healthcare setting such as hospitals, nursing homes, outpatient surgery centers, dialysis centers, and rehabilitation centers. According to the World Health Organization (WHO), hospital infections are those infections that occur within 48 hours of hospitalization or after 72 hours of discharge from hospitals or within 30 days after treatment. Hospital infections mostly originate in intensive care units (ICUs) of a hospital compared to other divisions. According to the Centers for Disease Control and Prevention (CDC), more than 2.8 million antibiotic-resistant infections occur in the U.S. each year, in the U.S. CDC also estimated that hospital infections accounted for 35,000 deaths.
Make an inquiry about the report for more information @ https://www.researchcorridor.com/inquiry/?id=27537
Major hospital infection therapeutics that are available in the global market has been categorized into three major drug segments, namely, antibacterial, antiviral, and antifungal drugs. Some of the major types of hospital infections include hospital-acquired pneumonia, urinary tract infections, gastrointestinal disorders, bloodstream infections, surgical site infections, and other hospital infections. Major driving factors for the growth of the hospital infection therapeutics market include increasing prevalence of various hospital infections, aging population, increasing healthcare awareness, and demand for improved therapeutic drugs. However, increasing multi-drug resistance that has rendered many drugs obsolete and the increasing number of surveillance and infection control programs, such as, point prevalence survey by ECDC, Europe, and HAI prevalence survey by CDC, U.S., may restrain the growth of this market. But, increasing multi-drug resistance and demand for improved infection treatment drugs have induced various drug developers and manufacturers to develop advanced therapeutic drugs. Several drugs that are in their phase III clinical trials will soon be commercialized during the forecast period and will add to the growth of this market in the future. Some of the major drugs that are in their late-stage clinical trials are Ceftolozane/Tazobactam, Dalvance, Delafloxacin, MK-3415A, Surotomycin, Eravacycline, and Tedizolid among others.
North America dominates the global hospital infection therapeutics market, in terms of revenue, followed by the European market in 2019. Major factors responsible for the leading position of the North American market are the high prevalence of various hospital infections, rising number of multidrug-resistant microbial pathogens, and increasing demand for advanced therapeutics. High awareness level along with the high purchasing capacity of the people is also contributing to the growth of the market in the region. Rising geriatric population in North America and Europe will add to the population of affected patients with hospital infections as aged patients exhibit lowered immunity levels. Thus, the increase in the affected patient population will require increased use of various therapeutic drugs, which in turn will contribute towards the growth of this market. Asia-Pacific is expected to show the highest rate of growth in the global hospital infection therapeutics market during the forecast period 2020 to 2027. Some of the major factors responsible for high growth rate are rapidly increasing prevalence of hospital-acquired infections in the region, rising awareness and demand for new and improved hospital infection treatment drugs, and increasing healthcare infrastructure as well as the purchasing power of people in the region.
To know more about the study, request a free report sample @ https://www.researchcorridor.com/request-sample/?id=27537
Actavis plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Cubist Pharmaceuticals, Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., and Sanofi are some of the major players operating in the global hospital infection therapeutics market.
The global hospital infection therapeutics market is segmented as follows:
By Drug Type
- Antibacterial Drugs
- Antiviral Drugs
- Antifungal Drugs
By Major Infections
- Hospital-Acquired Pneumonia
- Surgical Site Infections
- Urinary Tract Infections
- Gastrointestinal Disorders
- Bloodstream Infections
- Other Hospital Infections
- North America
- Latin America
- Middle East & Africa
Contact Person: Mr. Vijendra Singh
Contact Email: email@example.com
- Global hazardous waste materials management market will grow significantly due to rising environmental concerns and related compliance requirements
- Rising prevalence of nosocomial infection is the major driving factor for hospital acquired disease testing market
- Proactive attitude about personal health and awareness about genetic disease to drive the growth of the direct-to-consumer genetic testing market
- Increasing Penetration of Digital Television Globally to Drive the Set-top Boxes Market
- Persistent Rise in the Plastics Manufacturing Industry to Spur the Plastic Welding Equipment Market